4o33
From Proteopedia
(Difference between revisions)
| Line 12: | Line 12: | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/PGK1_HUMAN PGK1_HUMAN]] In addition to its role as a glycolytic enzyme, it seems that PGK-1 acts as a polymerase alpha cofactor protein (primer recognition protein). | [[http://www.uniprot.org/uniprot/PGK1_HUMAN PGK1_HUMAN]] In addition to its role as a glycolytic enzyme, it seems that PGK-1 acts as a polymerase alpha cofactor protein (primer recognition protein). | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Drugs that can protect against organ damage are urgently needed, especially for diseases such as sepsis and brain stroke. We discovered that terazosin (TZ), a widely marketed alpha1-adrenergic receptor antagonist, alleviated organ damage and improved survival in rodent models of stroke and sepsis. Through combined studies of enzymology and X-ray crystallography, we discovered that TZ binds a new target, phosphoglycerate kinase 1 (Pgk1), and activates its enzymatic activity, probably through 2,4-diamino-6,7-dimethoxyisoquinoline's ability to promote ATP release from Pgk1. Mechanistically, the ATP generated from Pgk1 may enhance the chaperone activity of Hsp90, an ATPase known to associate with Pgk1. Upon activation, Hsp90 promotes multistress resistance. Our studies demonstrate that TZ has a new protein target, Pgk1, and reveal its corresponding biological effect. As a clinical drug, TZ may be quickly translated into treatments for diseases including stroke and sepsis. | ||
| + | |||
| + | Terazosin activates Pgk1 and Hsp90 to promote stress resistance.,Chen X, Zhao C, Li X, Wang T, Li Y, Cao C, Ding Y, Dong M, Finci L, Wang JH, Li X, Liu L Nat Chem Biol. 2014 Nov 10. doi: 10.1038/nchembio.1657. PMID:25383758<ref>PMID:25383758</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
== References == | == References == | ||
<references/> | <references/> | ||
| Line 17: | Line 25: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Phosphoglycerate kinase]] | [[Category: Phosphoglycerate kinase]] | ||
| - | [[Category: Finci, L I | + | [[Category: Finci, L I]] |
| - | [[Category: Li, X L | + | [[Category: Li, X L]] |
| - | [[Category: Wang, J H | + | [[Category: Wang, J H]] |
[[Category: Enzyme-drug complex]] | [[Category: Enzyme-drug complex]] | ||
[[Category: Transferase-transferase activator complex]] | [[Category: Transferase-transferase activator complex]] | ||
[[Category: Transferase-transferase activitor complex]] | [[Category: Transferase-transferase activitor complex]] | ||
Revision as of 05:57, 26 November 2014
Crystal Structure of human PGK1 3PG and terazosin(TZN) ternary complex
| |||||||||||
